PATENT COOPERATION TREA

From the INTERNATIONAL BUREAU

PCT

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

ZEALAND PHARMA A/S Smedeland 26B DK-2600 Glostrup DANEMARK

MODTAGET 26 JAN. 2004

IMPORTANT NOTICE

Date of mailing (day/month/year) 15 January 2004 (15.01.2004)

Applicant's or agent's file reference

International application No.

022-2003 WO1

PCT/DK2003/000463

International filing date (day/month/year) 02 July 2003 (02.07.2003)

Priority date (day/month/year) 04 July 2002 (04.07.2002)

Applicant

ZEALAND PHARMA A/S et al

Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this notice:

AU, AZ, BY, CH, CN, CO, DE, DZ, EP, HU, JP, KG, KP, KR, MD, MK, MZ, RU, TM, US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

AE, AG, AL, AM, AP, AT, BA, BB, BG, BR, BZ, CA, CR, CU, CZ, DK, DM, EA, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, KE, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MG, MN, MW, MX, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, SY, TJ, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

- Enclosed with this notice is a copy of the international application as published by the International Bureau on 15 January 2004 (15.01.2004) under No. WO 2004/005342
- TIME LIMITS for filing a demand for international preliminary examination and for entry into the national phase

The applicable time limit for entering the national phase will, subject to what is said in the following paragraph, be 30 MONTHS from the priority date, not only in respect of any elected Office if a demand for international preliminary examination is filed before the expiration of 19 months from the priority date, but also in respect of any designated Office, in the absence of filing of such demand, where Article 22(1) as modified with effect from 1 April 2002 applies in respect of that designated Office. For further details, see PCT Gazette No. 44/2001 of 1 November 2001, pages 19926, 19932 and 19934, as well as the PCT Newsletter, October and November 2001 and February 2002 issues.

In practice, time limits other than the 30-month time limit will continue to apply, for various periods of time, in respect of certain designated or elected Offices. For regular updates on the applicable time limits (20, 21, 30 or 31 months, or other time limit), Office by Office, refer to the PCT Gazette, the PCT Newsletter and the PCT Applicant's Guide, Volume II, National Chapters, all available from WIPO's Internet site, at http://www.wipo.int/pct/en/index.html.

For filing a demand for international preliminary examination, see the PCT Applicant's Guide, Volume I/A, Chapter IX. Only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination (at present, all PCT Contracting States are bound by Chapter II).

It is the applicant's sole responsibility to monitor all these time limits.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva-20, Switzerland

Authorized officer

Gijsbertus Beijer - Carlos Roy

Facsimile No.(41-22) 740.14.35

Telephone No.(41-22) 338.91.11

Form PCT/IB/308 (April 2002)

TIONAL SEARCH REPORT INTER

Inter al Application No PCTytik 03400463

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K14/575 C07K14/605 $//C_{-15}/06$, A61K38/26 A61P3/10 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K A61K C07D C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of	the relevant passages	Relevant to claim No.	
X	WO 99 43708 A (MADSEN KJELD ; AS (DK); HUUSFELDT PER OLAF (2 September 1999 (1999-09-02) claim 89		1-78	
X	WO 01 32158 A (SQUIBB BRISTOL; PIPER BETH ANNE (US)) 10 May 2001 (2001-05-10) claim 69	MYERS CO	1-78	
x	US 6 358 924 B1 (HOFFMANN JAM) 19 March 2002 (2002-03-19) claim 11	ES ARTHUR)	1-78	
x	WO 01 04156 A (LARSEN BJARNE I SOEREN (DK); MIKKELSEN JENS DA (DK)) 18 January 2001 (2001-01 claims 1-48	AMSGAARD	1-78	
- 1	,	-/	-	
X Furthe	er documents are listed in the continuation of box C.	X Patent family members are listed i	n annex.	
*Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another diation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search		cited to understand the principle of the invention "X" document of particular relevance; the cleannot be considered novel or cannot involve an inventive step when the doc "Y" document of particular relevance; the cleannot be considered to involve an inventive and ocument is combined with one or more ments, such combination being obvious in the art. "&" document member of the same patent for the same patent for mailing of the international sear	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family Date of malling of the international search report	
30	September 2003	2 2. 10. 2003	·	
lame and ma	alling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswljk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer FERNANDO FARIETA	/EÖ	

INTERNATIONAL JEARCH REPORT

Intel ial Application No PCT/DK 03400463

	citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, or the received by	
Ė	EP 1 329 458 A (ZEALAND PHARMA AS) 23 July 2003 (2003-07-23) claim 6	1-78
X	ANDREW A. YOUNG ET AL: "Studies in Obese Diabetic (ob/ob, db/db) Mice, Diabetic Fatty Zucker Rats, and Diabetic Rhesus Monkeys (Macaca mulatta)" DIABETES, vol. 48, May 1999 (1999-05), pages 1026-1034, XP002256109 figures 1,2	1-78
x	LISA JUNTTI-BERGGREN ET AL: "The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients" DIABETES CARE, vol. 19, no. 11, November 1996 (1996-11), pages 1200-1206, XP002256110 figure 1	1-78
X	DAVID G. PARKES ET AL: "Insulinotropic Actions of Exendin-4 and Glucagon-Like Peptide-1 In Vivo and In Vitro "METABOLISM, vol. 50, no. 5, May 2001 (2001-05), pages 583-589, XP002256111 figure 2	1-78
A	RÉMY BURCELIN ET AL: "Long-Lasting Antidiabetic Effect of a Dipeptidyl Peptidase IV-Resistant Analog of Glucagon-Like Peptide-1" METABOLISM, vol. 48, no. 2, February 1999 (1999-02), pages 252-258, XP002256112 figures 1,2	1-78
A	U RITZEL ET AL: "A synthetic glucagon-like peptide-1 analog with improved plasma stability" JOURNAL OF ENDOCRINOLOGY, vol. 159, 1998, pages 93-102, XP002256113 figures 3,4	1-78

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNAT! AL SEARCH REPORT

PC 17 UK 03/40463

		PC17DK 0	340403
	tion) DOCUMENTS CONSIDERED TO SERELEVANT		Relevant to claim No.
Category *	Citation of document, with indication, where appropriate, of the relevant passages		
A · ·	DORIS A. STOFFERS ET AL: "Insulinotropic Glucagon-Like Peptide 1 Agonists Stimulate Expression of Homeodomain Protein IDX-1 and Increase Islet Size in Mouse Pancreas" DIABETES, vol. 49, May 2000 (2000-05), pages 741-748, XP002256114 figure 3		1-78
	US 6 344 180 B1 (HOLST J J ET AL) 5 February 2002 (2002-02-05) claims 1-13		1-78
1			·
Ì			
			. · ·
{	·		
	•		
ſ	*•	ĺ	
	•		
Į			
	_		
}			
			•
	•		
		. }	
		}	

Box I	Observations where certain claims were found unsearchable (Continuation of Refit 1 of Restaure)
This Inte	ernalional Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: 1-78 because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment. of any additional fee.
з. 🔲	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark o	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

International Applica



Continuation of Box I.1

FURTHER INFORMATION CONTINUED FROM

Claims Nos.: 1-78

Claims 1-78 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (PCT Rule 39.1(iv)).

PCT/ISA/ 210

The wording "drug holiday" is defined (Description, page 11, lines 29-30) as the time interval between a first endpoint (start) and a second endpoint (finish). Claim 1 seems to comprise such definition by the wording "...without the continuous presence of the molecule".

According to W099/43708, the use of GLP-1 derivatives and exendin for the treatment of diabetes is known (See claim 89- W099/43708). Therefore, the term "drug holiday" appears to be unclear if it referring to the dose administrated, in that case the claims 40-78 comprise also therapy or diagnostic methods practiced on the human or animal body (PCT Rule 39.1(iv)).

Consequently, a search has been carried out for on the alleged effects of the compounds or compositions for GLP-1 derivatives and exendin. Further, the search has covered the general aspects of the invention to some extent, although it lacks the necessary precision in the definition of the subject matter due to the large quantity of material known within GLP-1 and exendin derivatives.

The search for the general concept of GLP-1 derivatives and exendin will retrieve a pertinent document only if this concept is described in general terms in a reference. Specific solutions previously known and falling under the general concept - but failing to mention this fact - are likely not to be revealed in such a search.

INTER****TIONAL SEARCH REPORT

patent family members

matic

Form PCT/ISA/210 (patent family annex) (July 1992)

Application No

PCTyUK 03400463

Intern

ublication Patent family Patent document Publication date member(s) cited in search report date 15-09-1999 02-09-1999 AU 3247799 A W0 9943708 Α 02-09-1999 9943708 A1 WO 06-12-2000 EP 1056775 A1 22-07-2003 2003522099 T JP 31-07-2001 6268343 B1 US 02-08-2001 2001011071 A1 US 29-11-2001 2001047084 A1 US 02-09-1999 9901571 A ZA 28-11-2002 US 2002177602 A1 10-05-2001 WO 0132158 Α 14-05-2001 ΑU 1082601 A 14-05-2001 AU 8022900 A 28-02-2003 106732 A BG 28-02-2003 106733 A BG 15-07-2003 BR 0015294 A 0015295 A 24-06-2003 BR 10-05-2001 CA 2389928 A1 10-05-2001 CA 2389931 A1 30-04-2003 1414862 T CN 15-01-2003 20021547 A3 CZ 06-11-2002 1253944 A2 ΕP 1229918 A2 14-08-2002 EP 28-06-2003 HU 0300218 A2 28-07-2003 0300642 A2 HU 24-06-2003 2003519621 JP 25-03-2003 2002062 A ,B LT 25-06-2003 2002063 A LT 24-06-2002 NO 20022086 A 24-06-2002 NO 20022087 A 01-04-2003 SK 4992002 A3 0132157 A2 10-05-2001 WO 0132158 A2 10-05-2001 WO US 2002183345 A1 05-12-2002 1617399 A 28-06-1999 B1 19-03-2002 AU US 6358924 2312190 A1 17-06-1999 CA EP 1049486 A1 08-11-2000 JP 2001525371 T 11-12-2001 US 2002123466 A1 05-09-2002 MO 9929336 A1 17-06-1999 1076066 A1 14-02-2001 WO 0104156 Α 18-01-2001 ΕP 242267 T 15-06-2003 AT ΑU 5966000 A 30-01-2001 2378431 A1 18-01-2001 CA 1376166 T 23-10-2002 CN 60003182 D1 10-07-2003 DE 0104156 A1 18-01-2001 WO EP 1196444 A1 17-04-2002 1329458 A2 23-07-2003 ΕP 12-02-2003 JP 2003505347 T 517012 A NZ 28-02-2003 US 6528486 B1 04-03-2003 ΕP 1196444 A1 17-04-2002 EP 1329458 Α 23-07-2003 14-02-2001 ΕP 1076066 A1 1329458 A2 23-07-2003 EP 242267 T 15-06-2003 AT

INTERNATIONAL SEARCH REPORT

patent family members orma PCI/UK 02400463 Publication Patent family Patent document Publication date member(s) cited in search report 30-01-2001 5966000 A ΑU EP 1329458 Α CA 2378431 A1 18-01-2001 23-10-2002 CN 1376166 T 10-07-2003 DE 60003182 D1 18-01-2001 WO 0104156 A1 12-02-2003 JP 2003505347 T 517012 A 28-02-2003 NZUS 6528486 B1 04-03-2003 02-01-2001 05-02-2002 ΑU 5489400 A US 6344180 В1 CA 2376473 A1 21-12-2000 EP 1185308 A2 13-03-2002 JP 2003502344 T 21-01-2003 0077039 A2 21-12-2000 WO 2003091507 A1 15-05-2003 US

Inten

ial Application No

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

— BLACK BORDERS
IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER.

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.